Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia

C.A. Dane-Stewart, Gerald Watts, J.C.L. Mamo, Hugh Barrett, I.J. Martins, Simon Dimmitt, Trevor Redgrave

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Background We have previously shown elevated fasting plasma concentrations of intestinal remnants, as reflected by apolipoprotein (apo) B-48 and remnant-like particle-cholesterol (RLP-C) in patients with heterozygous familial hypercholesterolaemia (FH). We now investigate the effect of an HMG-CoA reductase inhibitor (simvastatin) on chylomicron remnant metabolism using the measurement of fasting apoB-48 and RLP-C in FH patients after long- and short-term simvastatin therapy and after a wash-out period. We also piloted the response of a breath test, involving the measurement of the fractional catabolic rate (FCR) of an intravenously injected chylomicron remnant-like emulsion labeled with cholesteryl C-13-oleate.Methods Fifteen FH patients were studied after > 6 months 40 mg day(-1) simvastatin treatment (long-term), a wash-out period (4 weeks), and 4 weeks of simvastatin treatment (short-term). Apolipoprotein B-48 was determined by SDS-PAGE and Western blotting/enhanced chemiluminescence and RLP-C by an immunoseparation assay. The FCR of the chylomicron remnant-like emulsion was determined from the appearance of (CO2)-C-13 in the breath and by multicompartmental mathematical modelling.Results Both long- and short-term treatment with simvastatin were associated with decreases in the plasma concentration of apoB-48 (P
Original languageEnglish
Pages (from-to)493-499
JournalEuropean Journal of Clinical Investigation
Publication statusPublished - 2002


Dive into the research topics of 'Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia'. Together they form a unique fingerprint.

Cite this